XML 70 R59.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details) - USD ($) $ in Thousands | Jun. 30, 2020 | Dec. 31, 2019
--- | --- | ---
Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  |  | $ 50,593
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  | $ 36,152 |
Oragenics, Inc. | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  |  | 2,864
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Average Remaining Performance Period (Years) |  | 3 years 10 months 24 days |
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  | $ 2,823 |
Intrexon Energy Partners, LLC | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  |  | 8,362
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Average Remaining Performance Period (Years) |  | 3 years 8 months 12 days |
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  | $ 8,362 |
Intrexon Energy Partners II, LLC | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  |  | 12,843
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Average Remaining Performance Period (Years) |  | 4 years 4 months 24 days |
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  | $ 12,843 |
Fibrocell Science, Inc. | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  |  | 17,697
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Average Remaining Performance Period (Years) |  | 1 year |
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  | $ 3,308 |
Harvest start-up entities | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue | [1] |  | 6,993
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Average Remaining Performance Period (Years) |  | 4 years 8 months 12 days |
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue | [1] | $ 6,993 |
Other | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  |  | $ 1,834
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Average Remaining Performance Period (Years) |  | 2 years 3 months 18 days |
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 | Upfront and milestone payments |  |  |
Contract With Customer, Asset And Liability [Line Items] |  |  |
Deferred revenue |  | $ 1,823 |
[1] | As of June 30, 2020 and December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

X
- Definition [Line Items] for Contract With Customer, Asset And Liability [Table] + References No definition available. + Details
Name: | pgen_ContractWithCustomerAssetAndLiabilityLineItems
Namespace Prefix: | pgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-07-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_OragenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_FibrocellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_OtherCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |